How to buy Brainstorm Cell Therapeutics stock | $3.58

Brainstorm Cell Therapeutics Inc is a biotechnology business based in the US. Brainstorm Cell Therapeutics shares (BCLI) are listed on the NASDAQ and all prices are listed in US Dollars. Brainstorm Cell Therapeutics employs 39 staff and has a market cap (total outstanding shares value) of 0.00.

Brainstorm Cell Therapeutics stock price (NASDAQ: BCLI)

Use our graph to track the performance of BCLI stocks over time.

Brainstorm Cell Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-30.

Latest market close	$3.58
52-week range	$2.92 - $17.95
50-day moving average	$3.65
200-day moving average	$4.16
Wall St. target price	$11.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.88

Buy Brainstorm Cell Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Brainstorm Cell Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Brainstorm Cell Therapeutics Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Brainstorm Cell Therapeutics price performance over time

Historical closes compared with the close of $3.58 from 2021-05-28

1 week (2021-07-22)	N/A
1 month (2021-07-02)	-4.02%
3 months (2021-04-30)	3.17%
6 months (2021-01-29)	N/A

1 year (2020-07-29)	N/A
2 years (2019-07-29)	N/A
3 years (2018-07-29)	N/A
5 years (2016-07-29)	N/A

Brainstorm Cell Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-56.84%
Return on equity TTM	-134.3%
Profit margin	0%
Book value	$1.00
Market capitalisation	$127.8 million

TTM: trailing 12 months

Shorting Brainstorm Cell Therapeutics shares

There are currently 1.3 million Brainstorm Cell Therapeutics shares held short by investors – that's known as Brainstorm Cell Therapeutics's "short interest". This figure is 5.3% down from 1.4 million last month.

There are a few different ways that this level of interest in shorting Brainstorm Cell Therapeutics shares can be evaluated.

Brainstorm Cell Therapeutics's "short interest ratio" (SIR)

Brainstorm Cell Therapeutics's "short interest ratio" (SIR) is the quantity of Brainstorm Cell Therapeutics shares currently shorted divided by the average quantity of Brainstorm Cell Therapeutics shares traded daily (recently around 398861.44578313). Brainstorm Cell Therapeutics's SIR currently stands at 3.32. In other words for every 100,000 Brainstorm Cell Therapeutics shares traded daily on the market, roughly 3320 shares are currently held short.

However Brainstorm Cell Therapeutics's short interest can also be evaluated against the total number of Brainstorm Cell Therapeutics shares, or, against the total number of tradable Brainstorm Cell Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Brainstorm Cell Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Brainstorm Cell Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0412% of the tradable shares (for every 100,000 tradable Brainstorm Cell Therapeutics shares, roughly 41 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Brainstorm Cell Therapeutics.

Find out more about how you can short Brainstorm Cell Therapeutics stock.

Brainstorm Cell Therapeutics share dividends

We're not expecting Brainstorm Cell Therapeutics to pay a dividend over the next 12 months.

Have Brainstorm Cell Therapeutics's shares ever split?

Brainstorm Cell Therapeutics's shares were split on a 1:15 basis on 15 September 2014. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Brainstorm Cell Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Brainstorm Cell Therapeutics shares which in turn could have impacted Brainstorm Cell Therapeutics's share price.

Brainstorm Cell Therapeutics share price volatility

Over the last 12 months, Brainstorm Cell Therapeutics's shares have ranged in value from as little as $2.92 up to $17.95. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Brainstorm Cell Therapeutics's is 0.0261. This would suggest that Brainstorm Cell Therapeutics's shares are less volatile than average (for this exchange).

Brainstorm Cell Therapeutics overview

Brainstorm Cell Therapeutics Inc. , a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc.

Frequently asked questions

What percentage of Brainstorm Cell Therapeutics is owned by insiders or institutions?
Currently 17.572% of Brainstorm Cell Therapeutics shares are held by insiders and 23.011% by institutions. How many people work for Brainstorm Cell Therapeutics?
Latest data suggests 39 work at Brainstorm Cell Therapeutics. When does the fiscal year end for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics's fiscal year ends in December. Where is Brainstorm Cell Therapeutics based?
Brainstorm Cell Therapeutics's address is: 1325 Avenue of Americas, New York, NY, United States, 10019 What is Brainstorm Cell Therapeutics's ISIN number?
Brainstorm Cell Therapeutics's international securities identification number is: US10501E2019 What is Brainstorm Cell Therapeutics's CUSIP number?
Brainstorm Cell Therapeutics's Committee on Uniform Securities Identification Procedures number is: 10501E102